Objectives: To investigate whether there is a temporal relationship between vaccination and the onset of type 1 immune-mediated polyarthritis in dogs.
Materials And Methods: Retrospective case-control study: 39 dogs from a referral hospital with a diagnosis of type 1 immune-mediated polyarthritis were age-matched with 78 control dogs with other diagnoses. A temporal association between vaccination and polyarthritis was considered positive if recent vaccination had been performed within 28 days of the onset of clinical signs of immune-mediated polyarthritis. The odds ratio association of recent vaccination with immune-mediated polyarthritis was calculated using matched case-control methods.
Results: Of the 39 dogs in the type 1 immune-mediated polyarthritis group, four had been vaccinated within 28 days before onset of clinical signs compared to six dogs in the control group. The odds ratio for a dog developing type 1 immune-mediated polyarthritis if vaccinated within the last 28 days was estimated to be 1·44 (95% confidence interval 0·25 to 8·24, P = 0·88).
Clinical Significance: There was no evidence of a temporal relationship between vaccination and type 1 immune-mediated polyarthritis, although the large confidence interval on the odds ratio suggests a need for larger studies to confirm this finding.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jsap.12774 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Leflunomide-induced drug reaction eosinophilia systemic symptoms and haemophagocytic lymphohistiocytosis overlap syndrome with rheumatoid arthritis.
BMJ Case Rep
January 2025
Department of Infectious Diseases, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and haemophagocytic lymphohistiocytosis (HLH) are rare but severe immune-mediated diseases with overlapping clinical manifestations. We present a case of a woman in her late 40s with rheumatoid arthritis who developed DRESS/HLH overlap syndrome after starting hydroxychloroquine and leflunomide therapy. Despite corticosteroid treatment, her condition worsened, necessitating etoposide therapy.
View Article and Find Full Text PDFEupalinolide B alleviates rheumatoid arthritis through the promotion of apoptosis and autophagy via regulating the AMPK/mTOR/ULK-1 signaling axis.
Int Immunopharmacol
January 2025
Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei 230032, Anhui Province, China; Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei 230026, Anhui Province, China. Electronic address:
The excessive proliferation of fibroblast-like synoviocytes (FLS) leads to synovial hyperplasia, a key pathological hallmark of rheumatoid arthritis (RA). Eupalinolide B (EB), a sesquiterpene lactone of Eupatorium lindleyanum DC., has anti-inflammatory effects and anti-proliferative activity in tumor cells.
View Article and Find Full Text PDFMicrobiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs.
Ann Rheum Dis
January 2025
Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
The increasing prevalence of autoimmune and immune-mediated diseases (AIMDs) underscores the need to understand environmental factors that contribute to their pathogenesis, with the microbiome emerging as a key player. Despite significant advancements in understanding how the microbiome influences physiological and inflammatory responses, translating these findings into clinical practice remains challenging. This viewpoint reviews the progress and obstacles in microbiome research related to AIMDs, examining molecular techniques that enhance our understanding of microbial contributions to disease.
View Article and Find Full Text PDFSpecific immune response to and ability to control mycobacterial replication are not impaired in subjects with immune-mediated inflammatory disease and tuberculosis infection.
Front Immunol
January 2025
Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
Background: Subjects with immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis, with tuberculosis infection (TBI), have a high probability of progressing to tuberculosis disease (TB). We aim to characterize the impact of IMID on the immune response to (Mtb) in patients with TBI and TB disease.
Methods: We enrolled TBI and TB patients with and without IMID.
Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive review.
Autoimmun Rev
January 2025
Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address:
Tuberculosis (TB), caused by Mycobacterium TB, is the most significant infectious cause of mortality across the globe. While TB disease can prey on immunocompetent individuals, it is more likely to occur in immunocompromised individuals. Immune-mediated inflammatory diseases (IMIDs) are a group of diseases (rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis, psoriasis, hidradenitis suppurative, autoimmune blistering diseases, and others) where there may be a need for systemic immunosuppression to control the disease manifestations, treat symptoms and improve long term outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!